Clinical Trial Update: MAD Study to Assess the Safety, Tolerability, PKs and Efficacy of YJ001 for Spray Use in Patients With DPNP [Phase 1]

View source ↗

Summary

An ongoing Phase 1 MAD study assessing the safety, tolerability, pharmacokinetics, and efficacy of YJ001 spray in patients with diabetic peripheral neuropathic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Peripheral Neuropathy
• Painful Diabetic Neuropathy

Drugs mentioned

• YJ001

Snippet

Sponsor: Zhejiang Hanmai Pharmaceutical Technology Co., Ltd. | Conditions: Diabetic Peripheral Neuropathic Pain | Phase 1 | Status: RECRUITING